Sponsored

Imugene (ASX: IMU) to present CF33 oncolytic virus study at SITC annual meeting

August 03, 2023 06:56 AM IST | By Sonal Goyal
 Imugene (ASX: IMU) to present CF33 oncolytic virus study at SITC annual meeting
Image source: Company website

Highlights

  • Imugene’s CF33 oncolytic virus technology will be featured at one of the most prestigious immunotherapy events.
  • The technology has been accepted for a Trial-in-Progress Poster.
  • The event in the US during early November, would open opportunities for discussion and networking with oncology community members.

ASX-listed biotechnology group Imugene Limited (ASX: IMU) shared that its CF33 oncolytic virus technology will be featured at the Society for Immunotherapy of Cancer (SITC) annual meeting. The event will be held in San Diego, the US, on 1-5 November 2023. 

The prestigious immunotherapy event, SITC 2023, showcases advanced research presentations by a number of experts, oral and poster abstract presentations. Also, the event creates opportunities for discussion and networking with the experts in the oncology community.

Data Source: Company update

About Imugene

Imugene is focused on developing new and novel immunotherapies. Supported by a leading team of international cancer experts, the clinical stage immuno-oncology company is advancing its product pipeline comprising multiple immunotherapy B-cell vaccine candidates and the oncolytic virotherapy (CF33).

IMU shares traded at AU$0.096 apiece at the time of writing on 3 August 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

Recent Articles

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.